Latest Tumors Stories
New treatment technique developed in partnership with Cancer Immune Biologics ATLANTA, Feb.
First-in-Class Agent is Well Tolerated in Liver Cancer Patients SAN ANTONIO, Jan.
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc.
Study to focus on mutations and deletions of CREBBP and EP300 genes in lymphomas SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc.
Researchers from the Karlsruhe Institute of Technology (KIT) have developed a computation method capable of adapting a non-deformed model to the underlying deformed surface profile of an organ during minimally invasive surgical procedures.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc.
A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer Institute (NCI) published today in the journal Clinical Cancer Research takes an important
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.